Results 61 to 70 of about 1,058,979 (232)

Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity

Advanced Science, EarlyView.
Repurposing the dense tumor stroma from a physical barrier into an anchoring scaffold, an engineered oncolytic adenovirus encoding IL15C‐CBD overcomes the immunosuppressive microenvironment in triple‐negative breast cancer. Intratumoral viral replication secretes this collagen‐anchored immunocytokine, forming a localized cytokine depot.
Yaqi Yang, Xiaoxiao Liu, Junqiang Ding, Jinliang Xu, Jianhua Zhang, Hanchang Zhang, Rong Yang, Sha Li, Lu Zheng, Runping Su, Yue Zhao, Jianxiao Wu, Hao Li, Changyou Zhan, Xihui Gao   +14 more
wiley   +1 more source

Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy

Pharmaceuticals, 2023
The approval of different cytokines as anti-neoplastic agents has been challenged by dose-limiting toxicities. Although reducing dose levels affords improved tolerability, efficacy is precluded at these suboptimal doses.
Nikolas T. Martin, Mathieu J. F. Crupi, Zaid Taha, Joanna Poutou, Jack T. Whelan, Sydney Vallati, Julia Petryk, Ricardo Marius, Bradley Austin, Taha Azad, Mason Boulanger, Tamara Burgess, Ilson Sanders, Camille Victoor, Bryan C. Dickinson, Jean-Simon Diallo, Carolina S. Ilkow, John C. Bell   +17 more
doaj   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes

Communications Biology, 2022
A secondary (but not primary) dose of the oncolytic virus, VSV, is captured by monocytes and promotes CD8 + T cell recruitment, thereby revealing a mechanism underlying the clinical benefit of repeat dosing in oncolytic virus therapy.
Victor Naumenko, Jahanara Rajwani, Madison Turk, Chunfen Zhang, Mandy Tse, Rachelle P. Davis, Daesun Kim, Andrea Rakic, Himika Dastidar, Shinia Van, Laura K. Mah, Esha K. Kaul, Vladimir P. Chekhonin, Douglas J. Mahoney, Craig N. Jenne   +14 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Measles virus causes immunogenic cell death in human melanoma [PDF]

, 2011
NoOncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Russell, S, Selby, P., Hadac, E., Donnelly, Oliver G, Jennings, V., Errington-Mais, F., Melcher, Alan A, Hadac, Elizabeth, Bond, J, Melcher, A.A., Bond, Jacquelyn, Selby, P, Bond, J., Peach, H., Vile, Richard, Steele, L., Vile, R., Hadac, E, Donnelly, O.G., Russell, Stephen, Harrington, K.J., Harrington, K, Peach, Howard, Steele, Lynette, Melcher, AA, Errington-Mais, Fiona, Harrington, Kevin, Russell, S., Phillips, Roger M., Pandha, H.S., Selby, Peter, Errington-Mais, F, Jennings, V, Scott, K, Phillips, RM, Phillips, Roger M, Scott, K., Pandha, Hardev, Vile, R, Jennings, Victoria, Steele, L, Pandha, H, Scott, Karen, Donnelly, OG, Peach, H   +44 more
core   +1 more source

Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities

Journal for ImmunoTherapy of Cancer
Background Heterologous oncolytic virus prime-boost vaccination is emerging as a promising cancer immunotherapy to establish potent antitumor immunity.
Marie-Claude Bourgeois-Daigneault, Victor Mullins-Dansereau, Marie-Lou Myre, Angelina Bardoul, Karen Geoffroy, Marco J Rallo Pita, Delphine Béland, Kim Leclerc Desaulniers, Dominic Guy Roy   +8 more
doaj   +1 more source

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference

Journal for ImmunoTherapy of Cancer, 2018
Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the immune system and limits virus propagation ...
Donald Bastin, Amelia S. Aitken, Adrian Pelin, Larissa A. Pikor, Mathieu J. F. Crupi, Michael S. Huh, Marie-Claude Bourgeois-Daigneault, John C. Bell, Carolina S. Ilkow   +8 more
doaj   +1 more source

High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactor

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The use of perfusion systems for the continuous cultivation of animal cells at high cell density (HCD) for the production of recombinant proteins, viruses, and viral vectors has many advantages. Besides an enhancement of volumetric productivity and high cell viability, the product quality can be improved through a steady‐state environment ...
Lennart Jacobtorweihe, Yasemin van Heuvel, Kathrina Scheiermann, Patrick Bongartz, Yvonne Genzel, Udo Reichl   +5 more
wiley   +1 more source

TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma

Molecular Therapy: Oncolytics, 2017
Oncolytic viruses are an emerging class of cancer therapeutics that couple cytotoxicity with the induction of an anti-tumor immune response. Host-virus interactions are complex and modulated by a tumor microenvironment whose immunosuppressive activities ...
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M. Swain, Julia Love, Joe Conner, Louis Boon, Timothy P. Cripe   +8 more
doaj   +1 more source